<Summary id="CDR0000258195" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Treatment of plasma cell neoplasms (including multiple myeloma, monoclonal gammopathy of undetermined significance, and plasmacytoma) includes observation, chemotherapy, radiation therapy, stem cell rescue, targeted therapy, immunotherapy, and supportive therapies. Learn more about how plasma cell neoplasms are diagnosed and treated in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq">Plasma Cell Neoplasms (including Multiple Myeloma) (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq">Plasma Cell Neoplasms (including Multiple Myeloma) (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000037974">multiple myeloma and other plasma cell neoplasms</TermRef></MainTopics><SummaryAbstract><Para id="_1">This PDQ cancer information summary has current information about treatment of plasma cell neoplasms (including multiple myeloma). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_2">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Adult Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>monoclonal gammopathy of undetermined significance (MGUS)</SummaryKeyWord><SummaryKeyWord>multiple myeloma</SummaryKeyWord><SummaryKeyWord>plasmacytoma</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Plasma Cell Neoplasms (Including Multiple Myeloma)   Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment</AltTitle><SummarySection id="_3"><Title>General Information About Plasma Cell  Neoplasms</Title><SummarySection id="_4"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_5">Plasma cell neoplasms are diseases in which the body makes too many plasma cells.</KeyPoint><Para id="_6"> <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">Plasma cells</GlossaryTermRef> develop from <GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B lymphocytes</GlossaryTermRef> (B cells), a type of <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cell</GlossaryTermRef> that is made in the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>. Normally, when <GlossaryTermRef href="CDR0000044123" dictionary="Cancer.gov" audience="Patient">bacteria</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045941" dictionary="Cancer.gov" audience="Patient">viruses</GlossaryTermRef> enter the body, some of the <GlossaryTermRef href="CDR0000045611" dictionary="Cancer.gov" audience="Patient">B cells</GlossaryTermRef> will change into plasma cells.  The plasma cells make <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> to fight bacteria and viruses, to stop <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease.<MediaLink ref="CDR0000763079" type="image/jpeg" alt="Multiple myeloma; drawing shows normal plasma cells, multiple myeloma cells (abnormal plasma cells), and antibodies. Also shown is red marrow inside bone, where plasma cells are made." language="en" placement="image-center" id="_7"><Caption language="en">Multiple myeloma. Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body. Normal plasma cells make antibodies to help the body fight infection and disease. As the number of multiple myeloma cells increases, more antibodies are made. This can cause the blood to thicken and keep the bone marrow from making enough healthy blood cells. Multiple myeloma cells also damage and weaken the bone.</Caption></MediaLink></Para><Para id="_8">Plasma cell <GlossaryTermRef href="CDR0000046264" dictionary="Cancer.gov" audience="Patient">neoplasms</GlossaryTermRef> are diseases in which  <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> plasma cells form <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef> in the bones or soft <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> of the body. The plasma cells also make an antibody <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef>, called <GlossaryTermRef href="CDR0000046299" dictionary="Cancer.gov" audience="Patient">M protein</GlossaryTermRef>, that is not needed by the body and does not help fight infection. These antibody proteins build up in the bone marrow and can cause the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> to thicken or can damage the <GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">kidneys</GlossaryTermRef>.  </Para></SummarySection><SummarySection id="_9"><KeyPoint id="_10">Plasma cell neoplasms can be benign (not cancer) or malignant (cancer).</KeyPoint><Para id="_11"><GlossaryTermRef href="CDR0000411379" dictionary="Cancer.gov" audience="Patient">Monoclonal gammopathy of undetermined significance</GlossaryTermRef> (MGUS) is not cancer but can become <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.
The following types of plasma cell neoplasms are cancer:</Para><ItemizedList id="_12" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000409750" dictionary="Cancer.gov" audience="Patient">Lymphoplasmacytic lymphoma</GlossaryTermRef> (also called Waldenström macroglobulinemia).  For more information, see <SummaryRef href="CDR0000062958#_398" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Non-Hodgkin Lymphoma Treatment</SummaryRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046231" dictionary="Cancer.gov" audience="Patient">Plasmacytoma</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">Multiple myeloma</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_13"><KeyPoint id="_14">There are several types of plasma cell neoplasms. </KeyPoint><Para id="_15">Plasma cell neoplasms include the following:</Para><SummarySection id="_16"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_17">Monoclonal gammopathy of undetermined significance (MGUS)</KeyPoint><Para id="_18">In this type of <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000046264" dictionary="Cancer.gov" audience="Patient">neoplasm</GlossaryTermRef>, less than 10% of the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> is made up of abnormal  <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cells</GlossaryTermRef> and there is no <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. The abnormal plasma cells make <GlossaryTermRef href="CDR0000046299" dictionary="Cancer.gov" audience="Patient">M protein</GlossaryTermRef>, which is sometimes found during a routine <GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046641" dictionary="Cancer.gov" audience="Patient">urine test</GlossaryTermRef>. In most patients, the amount of M protein stays the same and there are no <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>, or health problems.</Para><Para id="_19"> In some patients, <GlossaryTermRef href="CDR0000411380" dictionary="Cancer.gov" audience="Patient">MGUS</GlossaryTermRef> may later become a more serious <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef>, such as <GlossaryTermRef href="CDR0000045507" dictionary="Cancer.gov" audience="Patient">amyloidosis</GlossaryTermRef>, or cause problems with the kidneys, heart, or <GlossaryTermRef href="CDR0000373935" dictionary="Cancer.gov" audience="Patient">nerves</GlossaryTermRef>.  MGUS can also become cancer, such as <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef>,  <GlossaryTermRef href="CDR0000409750" dictionary="Cancer.gov" audience="Patient">lymphoplasmacytic lymphoma</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_20"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_21">Plasmacytoma</KeyPoint><Para id="_22">In this type of <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000046264" dictionary="Cancer.gov" audience="Patient">neoplasm</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> plasma cells (<GlossaryTermRef href="CDR0000045795" dictionary="Cancer.gov" audience="Patient">myeloma</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>) are in one place and form one <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef>, called a <GlossaryTermRef href="CDR0000046231" dictionary="Cancer.gov" audience="Patient">plasmacytoma</GlossaryTermRef>. Sometimes plasmacytoma can be <GlossaryTermRef href="CDR0000318813" dictionary="Cancer.gov" audience="Patient">cured</GlossaryTermRef>. There are two types of plasmacytoma.</Para><ItemizedList id="_23" Style="bullet"><ListItem>In isolated plasmacytoma  of bone, one <GlossaryTermRef href="CDR0000411386" dictionary="Cancer.gov" audience="Patient">plasma cell tumor</GlossaryTermRef> is found in the bone, less than 10% of the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> is made up of plasma cells, and there are no other <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. Plasmacytoma of the bone often becomes <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef>.</ListItem><ListItem>In extramedullary plasmacytoma, one plasma cell tumor is found in <GlossaryTermRef href="CDR0000045882" dictionary="Cancer.gov" audience="Patient">soft tissue</GlossaryTermRef> but not in the bone or the bone marrow. Extramedullary plasmacytomas commonly form in <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000439429" dictionary="Cancer.gov" audience="Patient">throat</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046618" dictionary="Cancer.gov" audience="Patient">tonsil</GlossaryTermRef>,  and <GlossaryTermRef href="CDR0000518299" dictionary="Cancer.gov" audience="Patient">paranasal sinuses</GlossaryTermRef>. </ListItem></ItemizedList><Para id="_24">Signs and <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> depend on where the tumor is.</Para><ItemizedList id="_25" Style="bullet"><ListItem>In bone, the plasmacytoma may cause pain or broken bones. </ListItem><ListItem>In soft tissue, the tumor may press on nearby areas and cause pain or other problems. For example, a plasmacytoma in the throat can make it hard to swallow. </ListItem></ItemizedList></SummarySection><SummarySection id="_26"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_27">Multiple myeloma</KeyPoint><Para id="_28">In <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cells</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045795" dictionary="Cancer.gov" audience="Patient">myeloma</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>) build up in the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> and form <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef> in many bones  of the body. These tumors may keep the bone marrow from making enough healthy <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> cells. Normally, the bone marrow makes <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cells</GlossaryTermRef> (immature cells) that become three types of mature blood cells:</Para><ItemizedList id="_29" Style="bullet"><ListItem>

<GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">Red blood cells</GlossaryTermRef> that carry <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef> and other substances to all <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> of the body. 
</ListItem><ListItem><GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">White blood cells</GlossaryTermRef> that fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease. 
</ListItem><ListItem><GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">Platelets</GlossaryTermRef> that form <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef> to help prevent bleeding. 
</ListItem></ItemizedList><Para id="_30">As the number of myeloma cells increases, fewer red blood cells, white blood cells, and platelets are made. The myeloma cells also damage and weaken the bone. </Para><Para id="_31">Sometimes multiple myeloma does not cause any <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. This is called <GlossaryTermRef href="CDR0000413932" dictionary="Cancer.gov" audience="Patient">smoldering multiple myeloma</GlossaryTermRef>. It may be found when a <GlossaryTermRef href="CDR0000688783" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046642" dictionary="Cancer.gov" audience="Patient">urine</GlossaryTermRef> test is done for another <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef>. Signs and symptoms may be caused by multiple myeloma or other conditions. Check with your doctor if you have any of the following:</Para><ItemizedList id="_32" Style="bullet"><ListItem>Bone pain, especially in the back or ribs.</ListItem><ListItem>Bones that break easily.</ListItem><ListItem><GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">Fever</GlossaryTermRef> for no known reason or frequent infections.</ListItem><ListItem>Easy bruising or bleeding.</ListItem><ListItem>Trouble breathing.</ListItem><ListItem>Weakness of the arms or legs.</ListItem><ListItem>Feeling very tired.</ListItem></ItemizedList><Para id="_33">A tumor can damage the bone and cause <GlossaryTermRef href="CDR0000045363" dictionary="Cancer.gov" audience="Patient">hypercalcemia</GlossaryTermRef> (too much <GlossaryTermRef href="CDR0000045632" dictionary="Cancer.gov" audience="Patient">calcium</GlossaryTermRef> in the blood). This can affect many <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> in the body, including the <GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">kidneys</GlossaryTermRef>, <GlossaryTermRef href="CDR0000269443" dictionary="Cancer.gov" audience="Patient">nerves</GlossaryTermRef>, heart, muscles, and <GlossaryTermRef href="CDR0000046447" dictionary="Cancer.gov" audience="Patient">digestive tract</GlossaryTermRef>, and cause serious health problems.</Para><Para id="_34">Hypercalcemia may cause the following signs and symptoms: 

</Para><ItemizedList id="_35" Style="bullet"><ListItem>Loss of <GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">appetite</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">Nausea</GlossaryTermRef> or <GlossaryTermRef href="CDR0000390324" dictionary="Cancer.gov" audience="Patient">vomiting</GlossaryTermRef>.</ListItem><ListItem>Feeling thirsty.</ListItem><ListItem>Frequent <GlossaryTermRef href="CDR0000046642" dictionary="Cancer.gov" audience="Patient">urination</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000407757" dictionary="Cancer.gov" audience="Patient">Constipation</GlossaryTermRef>.</ListItem><ListItem>Feeling very tired.</ListItem><ListItem>Muscle weakness. </ListItem><ListItem>Restlessness.</ListItem><ListItem><GlossaryTermRef href="CDR0000450096" dictionary="Cancer.gov" audience="Patient">Confusion</GlossaryTermRef> or trouble thinking.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_36"><KeyPoint id="_37">Multiple myeloma and other plasma cell neoplasms may cause a condition called amyloidosis.</KeyPoint><Para id="_38">In rare cases, multiple myeloma can cause peripheral nerves (nerves that are not in the brain or spinal cord) and organs to fail. This may be caused by a condition called amyloidosis. Antibody  proteins build up and stick together in peripheral nerves and organs, such as  the kidney and heart. This can cause the nerves and organs to become stiff and unable to work the way they should. </Para><Para id="_39">Amyloidosis may cause the following signs and symptoms:</Para><ItemizedList id="_40" Style="bullet"><ListItem>Feeling very tired.</ListItem><ListItem>Purple spots on the skin.</ListItem><ListItem>Enlarged tongue.</ListItem><ListItem><GlossaryTermRef href="CDR0000306496" dictionary="Cancer.gov" audience="Patient">Diarrhea</GlossaryTermRef>.</ListItem><ListItem>Swelling caused by <GlossaryTermRef href="CDR0000044669" dictionary="Cancer.gov" audience="Patient">fluid</GlossaryTermRef> in your body's tissues.</ListItem><ListItem>Tingling or numbness in your legs and feet.</ListItem></ItemizedList></SummarySection><SummarySection id="_41"><SectMetaData><SectionType>Risk factors</SectionType></SectMetaData><KeyPoint id="_42">Age can affect the risk of plasma cell neoplasms.</KeyPoint><Para id="_43">Anything that increases a person's chance of getting a disease is called a <GlossaryTermRef href="CDR0000045873" dictionary="Cancer.gov" audience="Patient">risk factor</GlossaryTermRef>. Not every person with one or more of these risk factors will develop plasma cell neoplasms, and they will develop in people who don't have any known risk factors. Talk with your doctor if you think you may be at risk.  </Para><Para id="_44">Plasma cell neoplasms are most common in people who are middle aged or older. For multiple myeloma  and plasmacytoma, other risk factors  include the following: </Para><ItemizedList id="_45" Style="bullet"> 
    <ListItem>Being Black.</ListItem><ListItem>Being male.</ListItem><ListItem>Having a <GlossaryTermRef href="CDR0000642019" dictionary="Cancer.gov" audience="Patient">personal history</GlossaryTermRef> of MGUS or plasmacytoma.</ListItem><ListItem>Being exposed to <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> or certain <GlossaryTermRef href="CDR0000643008" dictionary="Cancer.gov" audience="Patient">chemicals</GlossaryTermRef>.</ListItem> 
     
     
     
   </ItemizedList><Para id="_216">Studies about how racial, social, and financial factors affect access to treatment and rates of plasma cell neoplasms are ongoing.</Para></SummarySection><SummarySection id="_46"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_47">Tests that examine the blood, bone marrow, and urine are used to diagnose multiple myeloma and other plasma cell neoplasms.</KeyPoint><Para id="_48">In addition to asking about your <GlossaryTermRef href="CDR0000642019" dictionary="Cancer.gov" audience="Patient">personal</GlossaryTermRef> and <GlossaryTermRef href="CDR0000642015" dictionary="Cancer.gov" audience="Patient">family health history</GlossaryTermRef> and doing a <GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">physical exam</GlossaryTermRef>, your doctor may perform the following tests and procedures:</Para><ItemizedList id="_49" Style="bullet">
			 
			 <ListItem><Strong>Blood and urine     <GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> studies</Strong>:  A procedure in which a blood or urine sample is checked to measure the amounts of certain antibodies (immunoglobulins). For multiple myeloma, <GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">beta-2-microglobulin</GlossaryTermRef>, M protein, free light chains, and other proteins made by the myeloma cells are measured. A higher-than-normal amount of these substances can be a sign of disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000669655" dictionary="Cancer.gov" audience="Patient">Bone marrow aspiration and biopsy</GlossaryTermRef></Strong>: The removal of bone marrow, blood, and a small piece of bone by inserting a hollow needle into the hipbone or <GlossaryTermRef href="CDR0000549425" dictionary="Cancer.gov" audience="Patient">breastbone</GlossaryTermRef>. A <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef> views the bone marrow, blood, and bone under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> to look for abnormal cells. <MediaLink ref="CDR0000554337" type="image/jpeg" alt="Bone marrow aspiration and biopsy; drawing shows a patient lying face down on a table and a bone marrow needle being inserted into the hip bone. An inset shows a close up of the needle being inserted through the skin and hip bone into the bone marrow." language="en" placement="image-center" id="_50"><Caption language="en">Bone marrow aspiration and biopsy. After a small area of skin is numbed, a long, hollow needle is inserted through the patient's skin and hip bone into the bone marrow. A sample of bone marrow and a small piece of bone are removed for examination under a microscope.</Caption></MediaLink>The following tests may be done on the sample of tissue removed during the bone marrow aspiration and biopsy:

<ItemizedList id="_51" Style="dash"><ListItem><Strong><GlossaryTermRef href="CDR0000270737" dictionary="Cancer.gov" audience="Patient">Cytogenetic analysis</GlossaryTermRef></Strong>: A <GlossaryTermRef href="CDR0000046590" dictionary="Cancer.gov" audience="Patient">laboratory test</GlossaryTermRef> in which the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef> of cells in a sample of bone marrow are counted and checked for any changes, such as broken, missing, rearranged, or extra chromosomes. Changes in certain chromosomes may be a sign of cancer. Cytogenetic analysis is used to help <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> cancer, plan treatment, or find out how well treatment is working.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000460228" dictionary="Cancer.gov" audience="Patient">FISH</GlossaryTermRef> (fluorescence in situ hybridization)</Strong>: A laboratory test used to look at and count <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">genes</GlossaryTermRef> or chromosomes in cells and tissues. Pieces of <GlossaryTermRef href="CDR0000045671" dictionary="Cancer.gov" audience="Patient">DNA</GlossaryTermRef> that contain fluorescent dyes are made in the laboratory and added to a sample of a patient’s cells or tissues. When these dyed pieces of DNA attach to certain genes or areas of chromosomes in the sample, they light up when viewed under a fluorescent microscope. The FISH test is used to help diagnose cancer and help plan treatment.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000335066" dictionary="Cancer.gov" audience="Patient">Flow cytometry</GlossaryTermRef></Strong>: A laboratory test that measures the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of the cells, such as size, shape, and the presence of tumor (or other) <GlossaryTermRef href="CDR0000046636" dictionary="Cancer.gov" audience="Patient">markers</GlossaryTermRef> on the cell surface. The cells from a sample of a patient's bone marrow are stained with a fluorescent dye, placed in a fluid, and then passed one at a time through a beam of light. The test results are based on how the cells that were stained with the fluorescent dye react to the beam of light. This test is used to help diagnose and manage certain types of cancers, such as <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>. </ListItem></ItemizedList></ListItem>
			 <ListItem><Strong><GlossaryTermRef href="CDR0000044350" dictionary="Cancer.gov" audience="Patient">Skeletal</GlossaryTermRef> bone survey</Strong>: In a skeletal bone survey, <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> of all the bones in the body are taken. The x-rays are used to find areas where the bone is damaged. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body. </ListItem>
			 
			 
			 <ListItem><Strong><GlossaryTermRef href="CDR0000729979" dictionary="Cancer.gov" audience="Patient">Complete blood count (CBC) with differential</GlossaryTermRef></Strong>: A procedure in which a sample of blood is drawn and checked for the following:<ItemizedList id="_52" Style="dash"><ListItem>The number of red blood cells and platelets.</ListItem><ListItem>The number and type of white blood cells.</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the protein that carries <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef>) in the red blood cells.</ListItem><ListItem>	The portion of the blood sample made up of red blood cells.
</ListItem></ItemizedList> 
</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">Blood chemistry studies</GlossaryTermRef></Strong>: A procedure in which a blood sample is checked to measure the amounts of certain substances, such as <GlossaryTermRef href="CDR0000045632" dictionary="Cancer.gov" audience="Patient">calcium</GlossaryTermRef> or <GlossaryTermRef href="CDR0000044122" dictionary="Cancer.gov" audience="Patient">albumin</GlossaryTermRef>, released into the blood by <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease.</ListItem><ListItem><Strong>Twenty-four-hour urine test</Strong>: A test in which urine is collected for 24 hours to measure the amounts of certain substances. An unusual (higher or lower than normal) amount of a substance can be a sign of disease in the organ or tissue that  makes it. A higher than normal amount of protein may be a sign of multiple myeloma. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045788" dictionary="Cancer.gov" audience="Patient">MRI</GlossaryTermRef> (magnetic resonance imaging)</Strong>: A procedure that uses a magnet, <GlossaryTermRef href="CDR0000651209" dictionary="Cancer.gov" audience="Patient">radio waves</GlossaryTermRef>, and a computer to make a series of detailed pictures of areas inside the body. This procedure is also called  nuclear magnetic resonance imaging (NMRI). An MRI of the <GlossaryTermRef href="CDR0000415914" dictionary="Cancer.gov" audience="Patient">spine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046246" dictionary="Cancer.gov" audience="Patient">pelvis</GlossaryTermRef> may be used to find areas where the bone is damaged.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046140" dictionary="Cancer.gov" audience="Patient">PET scan</GlossaryTermRef> (positron emission tomography scan)</Strong>: A procedure to find <GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> tumor cells in the body.  A small amount of <GlossaryTermRef href="CDR0000774386" dictionary="Cancer.gov" audience="Patient">radioactive glucose</GlossaryTermRef> (sugar) is <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef>.  The PET <GlossaryTermRef href="CDR0000386220" dictionary="Cancer.gov" audience="Patient">scanner</GlossaryTermRef> rotates around the body and makes a picture of where glucose is being used in the body.  Malignant tumor cells show up brighter in the picture because they are more active and take up more glucose than normal cells do.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046033" dictionary="Cancer.gov" audience="Patient">CT scan</GlossaryTermRef> (CAT scan)</Strong>: A procedure that makes a series of detailed pictures of areas inside the body, such as the spine, taken from different angles.  The pictures are made by a computer linked to an x-ray machine. A <GlossaryTermRef href="CDR0000409764" dictionary="Cancer.gov" audience="Patient">dye</GlossaryTermRef> may be injected into a vein or swallowed to help the organs or tissues show up more clearly.  This procedure is also called computed tomography, computerized tomography, or computerized axial tomography. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000742485" dictionary="Cancer.gov" audience="Patient">PET-CT scan</GlossaryTermRef></Strong>: A procedure that combines the pictures from a positron emission tomography (PET) scan and a computed tomography (CT) scan. The PET and CT scans are done at the same time with the same machine. The combined scans give more detailed pictures of areas inside the body, such as the spine, than either scan gives by itself.</ListItem></ItemizedList></SummarySection><SummarySection id="_53"><SectMetaData><SectionType>Prognostic factors</SectionType></SectMetaData><KeyPoint id="_54">Certain factors affect prognosis (chance of recovery) and treatment options.</KeyPoint><Para id="_55">The <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> depends on the following:</Para><ItemizedList id="_56" Style="bullet">
    <ListItem>The type of plasma cell neoplasm.</ListItem><ListItem>The <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the disease.</ListItem><ListItem>Whether a certain immunoglobulin (antibody) is present.</ListItem><ListItem>Whether there are certain <GlossaryTermRef href="CDR0000046391" dictionary="Cancer.gov" audience="Patient">genetic</GlossaryTermRef> changes.</ListItem><ListItem>Whether the kidney is damaged.</ListItem>
    
    <ListItem>Whether the cancer <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">responds</GlossaryTermRef> to <GlossaryTermRef href="CDR0000589417" dictionary="Cancer.gov" audience="Patient">initial treatment</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046556" dictionary="Cancer.gov" audience="Patient">recurs</GlossaryTermRef> (comes back).</ListItem>
   </ItemizedList><Para id="_57">Treatment options depend on the following:</Para><ItemizedList id="_58" Style="bullet">
    <ListItem>The type of plasma cell neoplasm.</ListItem><ListItem>The age and general health of the patient.</ListItem><ListItem>Whether there are signs, symptoms, or health problems, such as <GlossaryTermRef href="CDR0000440109" dictionary="Cancer.gov" audience="Patient">kidney failure</GlossaryTermRef> or infection, related to the disease.</ListItem>
    <ListItem>Whether the cancer responds to initial treatment or recurs (comes back).</ListItem>
    
   </ItemizedList></SummarySection></SummarySection><SummarySection id="_59"><Title>Stages of Plasma Cell  Neoplasms</Title><SummarySection id="_60"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_61">There are no standard staging systems for monoclonal gammopathy of undetermined significance (MGUS) and plasmacytoma.</KeyPoint></SummarySection><SummarySection id="_62"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_63">After multiple myeloma has been diagnosed, tests are done to find out how much cancer is in the body.</KeyPoint><Para id="_64">The process used to find out the amount of  <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> in the body is called <GlossaryTermRef href="CDR0000046597" dictionary="Cancer.gov" audience="Patient">staging</GlossaryTermRef>. It is important to know
the <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> in order to plan treatment. </Para><Para id="_65">The following tests and
procedures may be used to find out how much cancer is in the body:

</Para><ItemizedList id="_66" Style="bullet"> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000044350" dictionary="Cancer.gov" audience="Patient">Skeletal</GlossaryTermRef> bone survey</Strong>: In a skeletal bone survey, <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> of all the bones in the body are taken. The x-rays are used to find areas where the bone is damaged. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body. </ListItem>
			 
			 
			  
		   
		   
		  <ListItem><Strong><GlossaryTermRef href="CDR0000045788" dictionary="Cancer.gov" audience="Patient">MRI</GlossaryTermRef> (magnetic resonance imaging)</Strong>: A procedure that uses a magnet, <GlossaryTermRef href="CDR0000651209" dictionary="Cancer.gov" audience="Patient">radio waves</GlossaryTermRef>, and a computer to make a series of detailed pictures of areas inside the body, such as the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>. This procedure is also called nuclear magnetic resonance imaging (NMRI). </ListItem><ListItem><Strong>Bone densitometry</Strong>: A procedure that uses a special type of x-ray to measure <GlossaryTermRef href="CDR0000407755" dictionary="Cancer.gov" audience="Patient">bone density</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_67"><KeyPoint id="_68">The stage of multiple myeloma is based on the levels of  beta-2-microglobulin and albumin in the blood.</KeyPoint><Para id="_69"><GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">Beta-2-microglobulin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044122" dictionary="Cancer.gov" audience="Patient">albumin</GlossaryTermRef> are found in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>. Beta-2-microglobulin is a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef>  found on <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cells</GlossaryTermRef>.  Albumin makes up the biggest part of the blood <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef>. It keeps <GlossaryTermRef href="CDR0000044669" dictionary="Cancer.gov" audience="Patient">fluid</GlossaryTermRef> from leaking out of <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef>.   It also brings <GlossaryTermRef href="CDR0000044697" dictionary="Cancer.gov" audience="Patient">nutrients</GlossaryTermRef> to <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef>, and carries <GlossaryTermRef href="CDR0000045713" dictionary="Cancer.gov" audience="Patient">hormones</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044744" dictionary="Cancer.gov" audience="Patient">vitamins</GlossaryTermRef>, <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>, and other substances, such as <GlossaryTermRef href="CDR0000045632" dictionary="Cancer.gov" audience="Patient">calcium</GlossaryTermRef>, all through the body. In the blood of patients with  <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef>, the amount of beta-2-microglobulin is increased and the amount of albumin is decreased.</Para></SummarySection><SummarySection id="_70"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_71">The following stages are used for multiple myeloma:</KeyPoint><SummarySection id="_72"><KeyPoint id="_73">Stage I multiple myeloma</KeyPoint><Para id="_74">In <GlossaryTermRef href="CDR0000044859" dictionary="Cancer.gov" audience="Patient">stage I multiple myeloma</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> levels are as follows: </Para><ItemizedList id="_75" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">beta-2-microglobulin</GlossaryTermRef> level is lower than 3.5 mg/L; and</ListItem><ListItem><GlossaryTermRef href="CDR0000044122" dictionary="Cancer.gov" audience="Patient">albumin</GlossaryTermRef> level is 3.5 g/dL or higher.</ListItem></ItemizedList></SummarySection><SummarySection id="_76"><KeyPoint id="_77">Stage II multiple myeloma</KeyPoint><Para id="_78">In <GlossaryTermRef href="CDR0000044863" dictionary="Cancer.gov" audience="Patient">stage II multiple myeloma</GlossaryTermRef>,   the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> levels are in between the levels for stage I and stage III.</Para></SummarySection><SummarySection id="_79"><KeyPoint id="_80">Stage III multiple myeloma</KeyPoint><Para id="_81">In <GlossaryTermRef href="CDR0000044866" dictionary="Cancer.gov" audience="Patient">stage III multiple myeloma</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> level of <GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">beta-2-microglobulin</GlossaryTermRef>  is 5.5 mg/L or higher and the patient also has one of the following:</Para><ItemizedList id="_82" Style="bullet"><ListItem>high levels of <GlossaryTermRef href="CDR0000354462" dictionary="Cancer.gov" audience="Patient">lactate dehydrogenase</GlossaryTermRef> (LDH); or</ListItem><ListItem>certain changes in the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_83"><KeyPoint id="_84">Plasma cell neoplasms may not respond to treatment or may come back after treatment.</KeyPoint><Para id="_85">Plasma cell <GlossaryTermRef href="CDR0000046264" dictionary="Cancer.gov" audience="Patient">neoplasms</GlossaryTermRef> are called      <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> when the number of plasma cells keeps going up even though treatment is given. Plasma cell neoplasms are called <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> when they have come back after treatment.</Para></SummarySection></SummarySection><SummarySection id="_88"><Title>Treatment Option Overview</Title><SummarySection id="_89"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_90">There are different types of treatment for  patients with plasma cell neoplasms.</KeyPoint><Para id="_91">Different types of treatments are available for  patients with <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000046264" dictionary="Cancer.gov" audience="Patient">neoplasms</GlossaryTermRef>. Some treatments are <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment), and some are being tested in <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>.  A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research study</GlossaryTermRef> meant to help improve current treatments or obtain information on new treatments for patients with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. When clinical trials show that a new treatment is better than the  standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.</Para></SummarySection><SummarySection id="_92"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_93">The following types of treatment are used:</KeyPoint><SummarySection id="_94"><KeyPoint id="_95">Chemotherapy</KeyPoint><Para id="_96"><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> is a cancer treatment that uses <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> to stop the growth of cancer <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>, either by killing the cells or by stopping   them from dividing.   When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef> or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef>).</Para><Para id="_97">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma">Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms</ExternalRef>.</Para></SummarySection><SummarySection id="_98"><KeyPoint id="_99">Other drug therapy</KeyPoint><Para id="_100"><GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">Corticosteroids</GlossaryTermRef> are <GlossaryTermRef href="CDR0000046601" dictionary="Cancer.gov" audience="Patient">steroids</GlossaryTermRef> that have <GlossaryTermRef href="CDR0000446109" dictionary="Cancer.gov" audience="Patient">antitumor</GlossaryTermRef> effects in <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef>.  
</Para></SummarySection><SummarySection id="_101"><KeyPoint id="_102">Targeted therapy</KeyPoint><Para id="_103"><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Several types of targeted therapy may be used to treat multiple myeloma and other plasma cell neoplasms. There are different types of targeted therapy:</Para><ItemizedList id="_104" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">Proteasome inhibitor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>: This  treatment blocks the action of proteasomes in cancer cells. A proteasome is a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> that removes other proteins no longer needed by the cell. When the proteins are not removed from the cell, they build up and may cause the cancer cell to die.    <GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">Bortezomib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000737706" dictionary="Cancer.gov" audience="Patient">carfilzomib</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000777065" dictionary="Cancer.gov" audience="Patient">ixazomib</GlossaryTermRef>  are proteasome inhibitors used in the treatment of multiple myeloma and other plasma cell neoplasms.</ListItem><ListItem><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibody</GlossaryTermRef> therapy: Monoclonal antibodies are <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. They may be used alone or to carry drugs, <GlossaryTermRef href="CDR0000046622" dictionary="Cancer.gov" audience="Patient">toxins</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> material directly to cancer cells. <GlossaryTermRef href="CDR0000776992" dictionary="Cancer.gov" audience="Patient">Daratumumab</GlossaryTermRef> and <GlossaryTermRef href="CDR0000777247" dictionary="Cancer.gov" audience="Patient">elotuzumab</GlossaryTermRef> are monoclonal antibodies used in the treatment of multiple myeloma and other plasma cell neoplasms. <GlossaryTermRef href="CDR0000514443" dictionary="Cancer.gov" audience="Patient">Denosumab</GlossaryTermRef> is a monoclonal antibody used to slow bone loss and reduce bone pain in patients with multiple myeloma.<EmbeddedVideo id="_215" ref="CDR0000801837" hosting="youtube" unique_id="dxnjAc-rqz8" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>monoclonal antibodies: how monoclonal antibodies treat cancer</VideoTitle><Caption language="en">How do  monoclonal antibodies work to treat cancer? This video shows how monoclonal antibodies, such as trastuzumab, pembrolizumab, and rituximab, block molecules cancer cells need to grow, flag cancer cells for destruction by the body’s immune system, or deliver harmful substances to cancer cells. </Caption></EmbeddedVideo></ListItem><ListItem><GlossaryTermRef href="CDR0000613897" dictionary="Cancer.gov" audience="Patient">BCL2</GlossaryTermRef> inhibitor therapy: This treatment blocks a protein called BCL2. Blocking this protein may help kill cancer cells and may make them more sensitive to anticancer drugs. <GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">Venetoclax</GlossaryTermRef> is a BCL2 inhibitor being studied  in the treatment of <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> multiple myeloma.</ListItem></ItemizedList><Para id="_108">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma">Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms</ExternalRef>.</Para></SummarySection><SummarySection id="_109"><KeyPoint id="_110">High-dose chemotherapy with  stem cell transplant</KeyPoint><Para id="_111">High <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of chemotherapy are given to kill cancer cells. Healthy cells, including <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>-forming cells, are also destroyed by the cancer treatment. <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> is a treatment to replace the blood-forming cells. <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> of the patient (<GlossaryTermRef href="CDR0000044912" dictionary="Cancer.gov" audience="Patient">autologous</GlossaryTermRef>) or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000044920" dictionary="Cancer.gov" audience="Patient">allogeneic</GlossaryTermRef>) and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells. <MediaLink ref="CDR0000765030" type="image/jpeg" alt="Donor stem cell transplant; (Panel 1): Drawing of stem cells being collected from a donor's bloodstream using an apheresis machine. Blood is removed from a vein in the donor's arm and flows through the machine where the stem cells are removed. The rest of the blood is then returned to the donor through a vein in their other arm. (Panel 2): Drawing of a health care provider giving a patient an infusion of chemotherapy through a catheter in the patient's chest. The chemotherapy is given to kill cancer cells and prepare the patient's body for the donor stem cells. (Panel 3): Drawing of a patient receiving an infusion of the donor stem cells through a catheter in the chest." language="en" placement="image-center" id="_112"><Caption language="en">Donor stem cell transplant. (Step 1): Four to five days before donor stem cell collection, the donor receives a medicine to increase the number of stem cells circulating through their bloodstream (not shown). The blood-forming stem cells are then collected from the donor through a large vein in their arm. The blood flows through an apheresis machine that removes the stem cells. The rest of the blood is returned to the donor through a vein in their other arm. (Step 2): The patient receives chemotherapy to kill cancer cells and prepare their body for the donor stem cells. The patient may also receive radiation therapy (not shown). (Step 3): The patient receives an infusion of the donor stem cells.</Caption></MediaLink></Para></SummarySection><SummarySection id="_113"><KeyPoint id="_114">Immunotherapy</KeyPoint><Para id="_115"><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> is a treatment that uses the patient's immune system to fight cancer.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.  This cancer treatment is a type of <GlossaryTermRef href="CDR0000045617" dictionary="Cancer.gov" audience="Patient">biologic therapy</GlossaryTermRef>.</Para><ItemizedList id="_116" Style="bullet"><ListItem>Immunomodulator therapy: <GlossaryTermRef href="CDR0000045458" dictionary="Cancer.gov" audience="Patient">Thalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000589401" dictionary="Cancer.gov" audience="Patient">pomalidomide</GlossaryTermRef> are immunomodulators used to treat multiple myeloma and other plasma cell neoplasms.</ListItem><ListItem><GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef>: This treatment changes the patient's <GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef> (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> are added to their surface in the laboratory. The changed cells are called <GlossaryTermRef href="CDR0000787969" dictionary="Cancer.gov" audience="Patient">chimeric antigen receptor</GlossaryTermRef> (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of multiple myeloma that has <GlossaryTermRef href="CDR0000046556" dictionary="Cancer.gov" audience="Patient">recurred</GlossaryTermRef> (come back).<MediaLink ref="CDR0000774647" type="image/jpeg" alt="CAR T-cell therapy; drawing of blood being removed from a vein in a patient’s arm to get T cells. Also shown is a special receptor called a chimeric antigen receptor (CAR) being made in the laboratory; the gene for CAR is inserted into the T cells and then millions of CAR T cells are grown. Drawing also shows the CAR T cells being given to the patient by infusion and binding to antigens on the cancer cells and killing them." language="en" placement="image-center" id="_117"><Caption language="en">CAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them.</Caption></MediaLink></ListItem></ItemizedList><Para id="_120">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma">Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms</ExternalRef>.</Para></SummarySection><SummarySection id="_121"><KeyPoint id="_122">Radiation therapy</KeyPoint><Para id="_123">Radiation therapy is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. <GlossaryTermRef href="CDR0000046686" dictionary="Cancer.gov" audience="Patient">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward the area of the body with cancer.</Para></SummarySection><SummarySection id="_126"><KeyPoint id="_127">Surgery</KeyPoint><Para id="_128"><GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">Surgery</GlossaryTermRef> to remove the tumor may be done. After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_129"><KeyPoint id="_130">Watchful waiting</KeyPoint><Para id="_131"><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> is closely <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitoring</GlossaryTermRef> a patient’s <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef> without giving any treatment until <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or symptoms appear or change.</Para></SummarySection></SummarySection><SummarySection id="_132"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_133">New types of treatment are being tested in clinical trials.  </KeyPoint><Para id="_134">This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the     <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><SummarySection id="_135"><KeyPoint id="_136">New combinations of therapies </KeyPoint><Para id="_137">Clinical trials are studying different  combinations of immunotherapy, chemotherapy, <GlossaryTermRef href="CDR0000045111" dictionary="Cancer.gov" audience="Patient">steroid therapy</GlossaryTermRef>, and  drugs. New treatment <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimens</GlossaryTermRef> using <GlossaryTermRef href="CDR0000798670" dictionary="Cancer.gov" audience="Patient">selinexor</GlossaryTermRef> are also being studied. </Para></SummarySection></SummarySection><SummarySection id="_138"><KeyPoint id="_139">Treatment for plasma cell neoplasms may cause side effects.</KeyPoint><Para id="_138_md_73">For information about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> caused by treatment for cancer, visit our <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef> page.</Para></SummarySection><SummarySection id="_140"><KeyPoint id="_141">Supportive care is given to lessen the problems caused by the disease or its treatment.

</KeyPoint><Para id="_142">This therapy controls problems or <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> caused by the disease or its treatment, and improves quality of life. <GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef> is given to treat problems caused by multiple myeloma and other plasma cell neoplasms. </Para><Para id="_143"> Supportive care may include the following:

</Para><ItemizedList id="_144" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045483" dictionary="Cancer.gov" audience="Patient">Plasmapheresis</GlossaryTermRef>: If the blood becomes thick with extra antibody proteins and interferes with <GlossaryTermRef href="CDR0000476484" dictionary="Cancer.gov" audience="Patient">circulation</GlossaryTermRef>, plasmapheresis is done to remove extra <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> and antibody proteins from the blood. In this procedure blood is removed from the patient and sent through a  machine that separates the plasma (the liquid part of the blood) from the blood cells. The patient's plasma contains the unneeded antibodies and is not returned to the patient. The normal blood cells are returned to the bloodstream along with donated plasma or a plasma  replacement. Plasmapheresis does not keep new antibodies from forming. </ListItem><ListItem><GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">Induction therapy</GlossaryTermRef> with stem cell transplant: If <GlossaryTermRef href="CDR0000045507" dictionary="Cancer.gov" audience="Patient">amyloidosis</GlossaryTermRef> occurs, treatment may include induction therapy followed by stem cell transplant using the patient's own stem cells. </ListItem><ListItem>Immunotherapy: Immunotherapy with thalidomide, lenalidomide, or pomalidomide is given to treat amyloidosis.</ListItem><ListItem>Targeted therapy: Targeted therapy with proteasome inhibitors is given to decrease how much <GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> M is in the blood and treat amyloidosis. Targeted therapy with daratumumab is given with or without other drugs to treat amyloidosis. Targeted therapy with a monoclonal antibody is given to slow bone loss and reduce bone pain.</ListItem><ListItem>Radiation therapy: Radiation therapy is given for bone <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000415914" dictionary="Cancer.gov" audience="Patient">spine</GlossaryTermRef>.</ListItem><ListItem> 
Chemotherapy: Chemotherapy is given to reduce back pain from <GlossaryTermRef href="CDR0000045371" dictionary="Cancer.gov" audience="Patient">osteoporosis</GlossaryTermRef> or <GlossaryTermRef href="CDR0000644309" dictionary="Cancer.gov" audience="Patient">compression fractures</GlossaryTermRef> of the spine.</ListItem><ListItem><GlossaryTermRef href="CDR0000044817" dictionary="Cancer.gov" audience="Patient">Bisphosphonate</GlossaryTermRef> therapy: Bisphosphonate therapy is given  to slow bone loss and reduce bone pain. For more information on bisphosphonates and problems related to their use, see <SummaryRef href="CDR0000062871#_232" url="/about-cancer/treatment/side-effects/mouth-throat/oral-complications-pdq">Oral Complications of Cancer Therapies</SummaryRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_146"><KeyPoint id="_147">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_146_md_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard treatment</GlossaryTermRef>.</Para><Para id="_146_md_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_146_md_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_148"><KeyPoint id="_149">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_148_md_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_148_md_30">Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trials search</ExternalRef> webpage. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para></SummarySection><SummarySection id="_150"><KeyPoint id="_151">Follow-up tests may be needed.</KeyPoint><Para id="_150_md_33">As you go through treatment, you  will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_150_md_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_152"><SectMetaData><SpecificDiagnosis ref="CDR0000040134">monoclonal gammopathy of undetermined significance</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Monoclonal Gammopathy of Undetermined Significance</Title><Para id="_153">For information about the treatments listed below, see the <SummaryRef href="CDR0000258195#_92" url="/types/myeloma/patient/myeloma-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_154">Treatment of <GlossaryTermRef href="CDR0000411379" dictionary="Cancer.gov" audience="Patient">monoclonal gammopathy of undetermined significance</GlossaryTermRef> (MGUS) is usually <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef>. Regular <GlossaryTermRef href="CDR0000688783" dictionary="Cancer.gov" audience="Patient">blood tests</GlossaryTermRef> to check the level of <GlossaryTermRef href="CDR0000046299" dictionary="Cancer.gov" audience="Patient">M protein</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> and  <GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">physical exams</GlossaryTermRef> to check for <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> will be done.</Para><Para id="_TrialSearch_152_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_155"><SectMetaData><SpecificDiagnosis ref="CDR0000041558">solitary osseous plasmacytoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Isolated Plasmacytoma of Bone </Title><Para id="_156">For information about the treatments listed below, see the <SummaryRef href="CDR0000258195#_92" url="/types/myeloma/patient/myeloma-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_157">Treatment of isolated <GlossaryTermRef href="CDR0000046231" dictionary="Cancer.gov" audience="Patient">plasmacytoma</GlossaryTermRef> of bone is usually <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> to the bone <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesion</GlossaryTermRef>.</Para><Para id="_TrialSearch_155_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_158"><SectMetaData><SpecificDiagnosis ref="CDR0000041865">extramedullary plasmacytoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Extramedullary Plasmacytoma</Title><Para id="_159">For information about the treatments listed below, see the <SummaryRef href="CDR0000258195#_92" url="/types/myeloma/patient/myeloma-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_160">Treatment of extramedullary <GlossaryTermRef href="CDR0000046231" dictionary="Cancer.gov" audience="Patient">plasmacytoma</GlossaryTermRef> may include the following:  </Para><ItemizedList id="_161" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> to the <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> and nearby <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">Surgery</GlossaryTermRef>, usually followed by radiation therapy.</ListItem><ListItem><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> after <GlossaryTermRef href="CDR0000589417" dictionary="Cancer.gov" audience="Patient">initial treatment</GlossaryTermRef>,  followed by radiation therapy,  surgery, or <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> if the tumor grows or causes <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_TrialSearch_158_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_162"><SectMetaData><SpecificDiagnosis ref="CDR0000042947">multiple myeloma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Multiple Myeloma</Title><Para id="_163">For information about the treatments listed below, see the <SummaryRef href="CDR0000258195#_92" url="/types/myeloma/patient/myeloma-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_164">Patients without <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> may not need treatment.  These patients can have <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef> until signs or symptoms appear.</Para><Para id="_165">When signs or symptoms appear, there are two categories for patients receiving treatment:</Para><ItemizedList id="_166" Style="bullet"><ListItem>Younger, fit patients who are eligible for a <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</ListItem><ListItem>Older, unfit patients who are not eligible for a stem cell transplant.</ListItem></ItemizedList><Para id="_167">Patients younger than 65 years are usually considered younger and fit. Patients older than 75 years are usually not eligible for a stem cell transplant.    For patients between the ages of 65 and 75 years, fitness is determined by their overall health and other factors.</Para><Para id="_168">The treatment of <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef> is usually done in phases:</Para><ItemizedList id="_169" Style="simple"><ListItem><Strong><GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">Induction therapy</GlossaryTermRef></Strong>: This is the first phase of treatment. Its goal is to reduce the amount of disease, and  may include one or more of the following:<ItemizedList id="_170" Style="bullet"><ListItem>For younger, fit patients (eligible for a transplant):<ItemizedList id="_171" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">bortezomib</GlossaryTermRef>) and a <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> (<GlossaryTermRef href="CDR0000776992" dictionary="Cancer.gov" audience="Patient">daratumumab</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">Corticosteroid</GlossaryTermRef> therapy (<GlossaryTermRef href="CDR0000045262" dictionary="Cancer.gov" audience="Patient">dexamethasone</GlossaryTermRef>).</ListItem></ItemizedList></ListItem><ListItem>For older, unfit patients (not eligible for a transplant):<ItemizedList id="_172" Style="bullet"><ListItem>Chemotherapy.</ListItem><ListItem>Targeted therapy with a proteasome inhibitor (bortezomib or <GlossaryTermRef href="CDR0000737706" dictionary="Cancer.gov" audience="Patient">carfilzomib</GlossaryTermRef>) or a monoclonal antibody (daratumumab).</ListItem><ListItem>Immunotherapy (lenalidomide).</ListItem><ListItem>Corticosteroid therapy (dexamethasone).</ListItem></ItemizedList></ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">Consolidation therapy</GlossaryTermRef></Strong>: This is the second phase of treatment. Treatment in the consolidation phase is to kill any remaining <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>. <GlossaryTermRef href="CDR0000346522" dictionary="Cancer.gov" audience="Patient">High-dose chemotherapy</GlossaryTermRef> is followed by either:<ItemizedList id="_174" Style="bullet"><ListItem>one <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous  stem cell transplant</GlossaryTermRef>, in which the patient's   <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cells</GlossaryTermRef> from the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> are used; or</ListItem><ListItem>two autologous  stem cell transplants followed by an autologous or <GlossaryTermRef href="CDR0000270732" dictionary="Cancer.gov" audience="Patient">allogeneic  stem cell transplant</GlossaryTermRef>, in which the  patient receives stem cells  from the blood or bone marrow of a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef>; or</ListItem><ListItem>one allogeneic stem cell transplant.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">Maintenance therapy</GlossaryTermRef></Strong>: After the <GlossaryTermRef href="CDR0000589417" dictionary="Cancer.gov" audience="Patient">initial treatment</GlossaryTermRef>, maintenance therapy is often given to help keep the disease in <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef> for a longer time. Several types of treatment are being studied for this use, including the following:<ItemizedList id="_175" Style="bullet"><ListItem>Chemotherapy.</ListItem><ListItem>Immunotherapy (lenalidomide).</ListItem><ListItem>Corticosteroid therapy (<GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> or dexamethasone).</ListItem><ListItem>Targeted therapy with a proteasome inhibitor (bortezomib or <GlossaryTermRef href="CDR0000777065" dictionary="Cancer.gov" audience="Patient">ixazomib</GlossaryTermRef>) or a monoclonal antibody (daratumumab).</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_TrialSearch_162_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_176"><SectMetaData><SpecificDiagnosis ref="CDR0000041876">refractory multiple myeloma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Relapsed or Refractory Multiple Myeloma</Title><Para id="_177">For information about the treatments listed below, see the <SummaryRef href="CDR0000258195#_92" url="/types/myeloma/patient/myeloma-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_178">Treatment of <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef> may include the following:</Para><ItemizedList id="_179" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> for patients whose disease is <GlossaryTermRef href="CDR0000045884" dictionary="Cancer.gov" audience="Patient">stable</GlossaryTermRef>.</ListItem>
	  
	  
	  
	  <ListItem>A different treatment than treatment already given, for patients whose <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> kept growing during treatment. See <SummaryRef href="CDR0000258195#_141" url="/types/myeloma/patient/myeloma-treatment-pdq">Multiple Myeloma</SummaryRef> treatment options.</ListItem>
	  <ListItem>The same <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> used before the relapse may be used if the relapse occurs one or more years after  initial treatment. See <SummaryRef href="CDR0000258195#_141" url="/types/myeloma/patient/myeloma-treatment-pdq">Multiple Myeloma</SummaryRef> treatment options.</ListItem></ItemizedList><Para id="_180">Drugs used may include the following:</Para><ItemizedList id="_181" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibodies</GlossaryTermRef> (<GlossaryTermRef href="CDR0000776992" dictionary="Cancer.gov" audience="Patient">daratumumab</GlossaryTermRef>, <GlossaryTermRef href="CDR0000777247" dictionary="Cancer.gov" audience="Patient">elotuzumab</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000800804" dictionary="Cancer.gov" audience="Patient">isatuximab</GlossaryTermRef>).</ListItem><ListItem>Targeted therapy with <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitors</GlossaryTermRef> (<GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">bortezomib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000737706" dictionary="Cancer.gov" audience="Patient">carfilzomib</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000777065" dictionary="Cancer.gov" audience="Patient">ixazomib</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000589401" dictionary="Cancer.gov" audience="Patient">pomalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045458" dictionary="Cancer.gov" audience="Patient">thalidomide</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">Corticosteroid</GlossaryTermRef> therapy.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef>.</ListItem><ListItem>A clinical trial of targeted therapy with a small molecule inhibitor (<GlossaryTermRef href="CDR0000798670" dictionary="Cancer.gov" audience="Patient">selinexor</GlossaryTermRef>) and corticosteroid therapy.</ListItem><ListItem>A clinical trial of targeted therapy with a <GlossaryTermRef href="CDR0000613897" dictionary="Cancer.gov" audience="Patient">BCL2</GlossaryTermRef> inhibitor (<GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">venetoclax</GlossaryTermRef>).</ListItem></ItemizedList><Para id="_TrialSearch_176_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_209"><Title>To Learn More About Plasma Cell  Neoplasms</Title><Para id="_210">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about multiple myeloma and other plasma cell neoplasms, see the following:</Para><ItemizedList id="_211" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/types/myeloma">Multiple Myeloma/Other Plasma Cell Neoplasms Home Page</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma">Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant">Stem Cell Transplants in Cancer Treatment</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">Immunotherapy to Treat Cancer</ExternalRef></ListItem></ItemizedList><Para id="_209_md_40">For general cancer information and other resources from the National Cancer Institute, visit:</Para><ItemizedList id="_209_md_41" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about treatment of plasma cell neoplasms (including multiple myeloma).  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Adult Treatment Editorial Board. PDQ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq">https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389437]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><PatientVersionOf ref="CDR0000062866"/><DateLastModified>2023-11-17</DateLastModified></Summary>
